8-K: Tivic Health Focuses on Vagus Nerve Stimulation, Reports Improved Margins and Reduced Losses

Tivic Health is shifting its focus to vagus nerve stimulation (VNS) while reporting significant improvements in gross margins and a reduction in net operating losses.

Summary

• Tivic Health has released its annual CEO letter to shareholders, highlighting key developments in 2024 and expectations for 2025.
• The company launched ClearUP 2.0, which improved customer experience and resolved technical issues from late 2023.
• Go-to-market partnerships with McKesson and Cardinal Health accelerated in the second half of the year.
• Customer reviews improved to 4.4 stars, and defect-related returns significantly decreased.
• The company restructured its supply chain, achieving a recurring gross margin greater than 65% in direct-to-consumer channels, a significant increase from less than 28% in 2023.
• Tivic is focusing on vagus nerve stimulation (VNS), a market projected to reach $21 billion in the next five years with a CAGR of 10.6%.
• The company's non-invasive cervical VNS (ncVNS) approach has shown best-in-industry effects on outcomes like heart rate variability and achieved comparable or better results than invasive implants.
• A pilot study with the Feinstein Institute of Bioelectronic Medicine demonstrated clinically meaningful changes in brain, cardiac, and nervous system activity using ncVNS.
• A second study is underway to optimize ncVNS parameters, with positive results so far.
• Tivic has identified targeted opportunities for its ncVNS approach exceeding $30 billion in annual market opportunity.
• The company has a robust IP portfolio with 16 issued patents and 10 pending patents.
• Tivic reduced its net operating loss by more than 30% in 2024.
• The company is exploring new opportunities to increase cash flow from the ClearUP business and plans to move into clinical trials for ncVNS in 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with significant improvements in financial metrics and promising developments in VNS technology. The company is making strategic moves to capitalize on a growing market, and the management's tone is optimistic.

Positives

• The launch of ClearUP 2.0 has improved customer experience and resolved technical issues.
• Partnerships with McKesson and Cardinal Health have accelerated, expanding market reach.
• Customer satisfaction has increased, as evidenced by improved reviews and reduced returns.
• The company has achieved a significant increase in gross margin to over 65% in direct-to-consumer channels.
• Tivic's non-invasive VNS technology has shown promising results, comparable to or better than invasive methods.
• The company has a strong intellectual property portfolio with 16 issued patents and 10 pending patents.
• Net operating losses have been reduced by more than 30%.

Risks

• The document contains forward-looking statements that involve substantial risks and uncertainties.
• Actual results could differ materially from those contained in any forward-looking statement.
• The company is still in the early stages of clinical trials for its ncVNS technology.
• The company needs to regain Nasdaq listing compliance.

Future Outlook

Tivic Health is focused on advancing its clinical programs for non-invasive cervical VNS (ncVNS) and expects this to be key to increasing long-term shareholder value. The company is also exploring new opportunities to increase cash flow from the ClearUP business and is evaluating options to regain Nasdaq listing compliance.

Management Comments

• Jennifer Ernst, CEO, stated that the company is proud of the improvements in the base business and the advances made with vagus nerve stimulation.
• The CEO also mentioned that the company accomplished all of this while slashing net operating loss by more than 30%.
• The CEO expressed excitement about the opportunities that lie ahead and looks forward to continuing the journey with investors, collaborators, and supporters in 2025.

Industry Context

The announcement highlights Tivic Health's strategic shift towards vagus nerve stimulation (VNS), a rapidly growing area in bioelectronic medicine. The company is positioning itself to capitalize on the increasing awareness and adoption of non-invasive VNS therapies, which are gaining traction as alternatives to traditional drug-based treatments. The VNS market is expected to grow significantly, and Tivic's focus on non-invasive methods aligns with the trend towards less invasive medical procedures.

Comparison to Industry Standards

• Tivic's non-invasive VNS system has shown best-in-industry effects on outcomes like heart rate variability, which is a key metric in assessing the effectiveness of VNS therapies.
• The company's ncVNS approach has achieved comparable or better results when compared to invasive implants, which are the current standard in the VNS market.
• Companies like LivaNova and ElectroCore are key players in the VNS market, primarily focusing on implanted devices. Tivic's non-invasive approach offers a less capital-intensive pathway to market.
• The $21 billion market forecast for VNS by Polaris Research indicates a significant growth opportunity, and Tivic's $30 billion potential market opportunity suggests a strong competitive position if they can successfully commercialize their technology.

Stakeholder Impact

• Shareholders can expect increased long-term value from the advancement of clinical programs for ncVNS.
• Customers will benefit from improved products and drug-free therapeutic solutions.
• Employees are recognized for their hard work and dedication.
• The company's success will positively impact the broader healthcare industry by advancing bioelectronic medicine.

Next Steps

• Tivic will complete the current work with the Feinstein Institute of Bioelectronic Medicine.
• The company will chart disease-specific clinical trials for ncVNS.
• Tivic will move closer to securing regulatory approvals for its ncVNS treatments.
• The company will explore new opportunities to increase cash flow from the ClearUP business.
• Tivic will evaluate options to maximize shareholder returns, including regaining Nasdaq listing compliance.

Key Dates

Keywords

vagus nerve stimulation, VNS, bioelectronic medicine, ClearUP, non-invasive, gross margin, clinical trials, intellectual property, net operating loss, Feinstein Institute